Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
1.
BMC Endocr Disord ; 22(1): 11, 2022 Jan 05.
Artículo en Inglés | MEDLINE | ID: mdl-34986816

RESUMEN

BACKGROUND: Primary macronodular adrenal hyperplasia (PMAH), previously termed ACTH-independent macronodular adrenal hyperplasia (AIMAH), is a rare cause of Cushing's syndrome usually characterized by functioning adrenal macronodules and increased cortisol production. METHODS: To screen and analyse the microRNA (miRNA) profile of PMAH in order to elucidate its possible pathogenesis, a miRNA microarray was used to test tissue samples from patients with familial PMAH, patients with sporadic PMAH and normal control samples of other nontumour adrenocortical tissues and identify characteristic microRNA expression signatures. Randomly selected miRNAs were validated by quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR). Furthermore, the key signalling pathways and miRNAs involved in PMAH pathogenesis were determined by gene ontology and pathway analysis. RESULTS: Characteristic microRNA expression signatures were identified for patients with familial PMAH (16 differentially expressed microRNAs) and patients with sporadic PMAH (8 differentially expressed microRNAs). The expression of the selected miRNAs was confirmed by qRT-PCR, suggesting the high reliability of the miRNA array analysis results. Pathway analysis showed that the most enriched pathway was the renal cell carcinoma pathway. Overexpression of miR-17, miR-20a and miR-130b may inhibit glucocorticoid-induced apoptosis in PMAH pathogenesis. CONCLUSION: We identified the miRNA signatures in patients with familial and sporadic PMAH. The differentially expressed miRNAs may be involved in the mechanisms of PMAH pathogenesis. Specific miRNAs, such as miR-17, miR-20a and miR-130b, may be new targets for further functional studies of PMAH.


Asunto(s)
Síndrome de Cushing/genética , Síndrome de Cushing/metabolismo , MicroARNs/metabolismo , Humanos , Análisis por Micromatrices
2.
Saudi Pharm J ; 28(12): 1877-1882, 2020 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-33020690

RESUMEN

BACKGROUND: Pharmacological treatments including antivirals (Lopinavir/Ritonavir), Immuno-modulatory and anti-inflammatory drugs including, Tocilizumab and Hydroxychloroquine (HCQ) has been widely investigated as a treatment for COVID-19.Despite the ongoing controversies, HCQ was recommended for managing mild to moderate cases in Saudi Arabia . However, to our knowledge, no previous studies have been conducted in Saudi Arabia to assess its effectiveness. METHODS: A hospital-based retrospective cohort study involving 161 patients with COVID-19 was conducted from March 1 to May 20, 2020. The study was conducted at Prince Mohammed bin Abdul Aziz Hospital (PMAH).The population included hospitalized adults (age ≥ 18 years) with laboratory-confirmed COVID-19. Each eligible patient was followed from the time of admission until the time of discharge. Patients were classified into two groups according to treatment type: in the HCQ group, patients were treated with HCQ; in the SC group, patients were treated with other antiviral or antibacterial treatments according to Ministry of Health (MOH) protocols.The outcomes were hospitalization days, ICU admission, and the need for mechanical ventilation.We estimated the differences in hospital length of stay and time in the ICU between the HCQ group and the standard care (SC) group using a multivariate generalized linear regression. The differences in ICU admission and mechanical ventilation were compared via logistic regression. All models were adjusted for age and gender variables. RESULTS: A total of 161 patients fulfilled the inclusion criteria. Approximately 59% (n = 95) received HCQ-based treatment, and 41% (n = 66) received SC. Length of hospital stay and time in ICU in for patients who received HCQ based treatment was shorter than those who received SC. Similarly, there was less need for ICU admission and mechanical ventilation among patients who received HCQ based treatment compared with SC, (8.6% vs. 10.7 and 3.1% vs. 9.1%). However, the regression analysis showed no significant difference between the two groups in terms of patient outcomes. CONCLUSION: HCQ had a modest effect on hospital length stay and days in ICU compared with SC. However, these results need to be interpreted with caution. Larger observational studies and RCTs that evaluate the efficacy of HCQ in COVID-19 patients in the Saudi population are urgently needed.

3.
J Endocr Soc ; 6(5): bvac041, 2022 May 01.
Artículo en Inglés | MEDLINE | ID: mdl-35402764

RESUMEN

Primary macronodular adrenal hyperplasia (PMAH) is considered a rare cause of adrenal Cushing syndrome, is pituitary ACTH-independent, generally results from bilateral adrenal macronodules (>1 cm), and is often associated with variable cortisol secretion, resulting in a heterogeneous clinical presentation. Recent advances in the molecular pathogenesis of PMAH have offered new insights into the comprehension of this heterogeneous and complex adrenal disorder. Different molecular mechanisms involving the actors of the cAMP/protein kinase A pathway have been implicated in the development of PMAH, including germline and/or somatic molecular defects such as hyperexpression of the G-protein aberrant receptors and pathogenic variants of MC2R, GNAS, PRKAR1A, and PDE11A. Nevertheless, since 2013, the ARMC5 gene is believed to be a major genetic cause of PMAH, accounting for more than 80% of the familial forms of PMAH and 30% of apparently sporadic cases, except in food-dependent Cushing syndrome in which ARMC5 is not involved. Recently, 2 independent groups have identified that the tumor suppressor gene KDM1A is responsible for PMAH associated specifically with food-dependent Cushing syndrome. Consequently, PMAH has been more frequently genetically associated than previously assumed. This review summarizes the most important aspects, including hormone secretion, clinical presentation, radiological imaging, and molecular mechanisms, involved in familial Cushing syndrome associated with PMAH.

4.
Diagnostics (Basel) ; 12(12)2022 Dec 02.
Artículo en Inglés | MEDLINE | ID: mdl-36553033

RESUMEN

Background: Primary macronodular adrenocortical hyperplasia (PMAH) is a rare form of adrenal Cushing's syndrome with incomplete penetrance which may be sporadic or autosomal dominant. The inactivation of the ARMC5 gene, a potential tumor suppressor gene, is one of the associated causes of PMAH. This study aimed to identify the variant responsible for Iranian familial PMAH. Methods: The proband, a 44-year-old woman, was directed to whole-exome sequencing (WES) of the blood sample to discover a germline variant. In addition, the identified causative variant was confirmed and segregated in other and available unaffected family members. Results: The novel germline heterozygous missense variant, c.2105C>A in the ARMC5 gene, was found, and the same germline variant as the proband was confirmed in two affected sisters. This variant was detected in the brother of the proband with an asymptomatic condition and this considered because of incomplete penetrance and age-dependent appearance. The function of the ARMC5 protein would be damaged by the identified variant, according to in silico and computer analyses that followed. Conclusion: The new germline ARMC5 variation (c.2105C>A, (p. Ala702Glu)) was interpreted as a likely pathogenic variant based on ACMG and Sherloc standards. PMAH may be diagnosed early using genetic testing that shows inherited autosomal dominant mutations in the ARMC5 gene.

5.
J Endocr Soc ; 4(8): bvaa083, 2020 Aug 01.
Artículo en Inglés | MEDLINE | ID: mdl-32724871

RESUMEN

PURPOSE: This prospective study presents the results of a new approach in the treatment of primary macronodular adrenal hyperplasia (PMAH), with simultaneous total adrenalectomy of the larger adrenal gland and partial adrenalectomy of the contralateral adrenal gland (adrenal-sparing surgery). MATERIALS AND METHODS: We performed a prospective study including 17 patients with PMAH treated surgically with adrenal-sparing surgery in a tertiary referral hospital, with a median follow-up of 41 months. Clinical, hormonal, and genetic parameters were evaluated before surgery and during follow-up. All patients had at least 1 radiological examination before and after the procedure. RESULTS: Among the 17 patients, all but 1 patient had complete hypercortisolism control, and 12 recovered normal adrenal function after surgery. Significant improvement in clinical parameters was observed: weight loss (P = .004); reduction of both systolic (P = .001) and diastolic (P = .001) blood pressure; and reduction in the number of antihypertensive drugs (P < .001). Intra-, peri-, and postoperative complications were not observed. CONCLUSION: Adrenal-sparing surgery is a safe and feasible procedure to treat patients with PMAH, providing a substantial chance of hypercortisolism control without the disadvantages of lifetime corticosteroid replacement.

6.
J Endocr Soc ; 3(10): 1837-1846, 2019 Oct 01.
Artículo en Inglés | MEDLINE | ID: mdl-31555754

RESUMEN

CONTEXT: Primary macronodular adrenal hyperplasia (PMAH) is a rare type of Cushing or subclinical Cushing syndrome and is associated with bilateral multinodular formation. ARMC5 is one of the responsible genes for PMAH. OBJECTIVES: This study was performed to identify the genotype-phenotype correlation of ARMC5 in a cohort of Japanese patients. PATIENTS AND METHODS: Fourteen patients with clinically diagnosed PMAH and family members of selected patients were studied for ARMC5 gene alteration and clinical phenotype. The associated nonadrenal tumor tissues were also studied. RESULTS: Of fourteen patients with PMAH, 10 had pathogenic or likely pathogenic variants of ARMC5. We found two variants. Five unrelated patients had identical variants (p.R619*). In two patients, the variant was found in offspring with the asymptomatic or presymptomatic state. Six of ten patients who tested positive for the ARMC5 pathogenic or likely pathogenic variant carried nonadrenal tumors; however, no loss of heterozygosity (LOH) or second hit of the ARMC5 gene was evident. The ARMC5 variant-positive group showed a significantly higher basal cortisol level. Furthermore, age-dependent cortisol hypersecretion was seen in the ARMC5 variant-positive group. CONCLUSIONS: ARMC5 pathogenic variants are common (71%) in Japanese patients with PMAH. p.R619* might be a hot spot in Japanese patients with PMAH. Asymptomatic or presymptomatic pathogenic variant carriers were found among the family members of the patients. Although 50% of ARMC5 variant carriers had nonadrenal neoplastic lesions, no LOH or second hit of ARMC5 in the tumor tissues was evident. The ARMC5 variant-positive mutant group showed a higher basal cortisol level than the negative group.

7.
Mol Cell Endocrinol ; 460: 36-46, 2018 01 15.
Artículo en Inglés | MEDLINE | ID: mdl-28676429

RESUMEN

The participation of aberrant receptors and intra-adrenal ACTH in hyperplastic tissue are considered mechanisms that regulate hypercortisolism in PMAH. Additionally, germline ARMC5 mutations have been described as the most frequent genetic abnormality found in patients diagnosed with PMAH. Previous functional studies analyzed ARMC5 role using H295R cells. Therefore, we investigated the role of ARMC5 in cell cultures obtained from PMAH nodules containing steroidogenic cells, aberrant receptors and intra-adrenal ACTH. ARMC5 silencing in non-mutated PMAH cell cultures decreased steroidogenesis-related genes and increased CCNE1 mRNA expression and proliferative capacity without affecting cell viability. Additionally, ARMC5 overexpression induced cell death in PMAH mutated cell cultures, thereby decreasing cell viability. We confirmed the role of ARMC5 as an important pro-apoptotic protein involved in PMAH-related steroidogenesis. We also report for the first time the involvement of ARMC5 in controlling proliferation and regulating cell cycle in PMAH cell cultures; these effects need to be explored further.


Asunto(s)
Glándulas Suprarrenales/metabolismo , Glándulas Suprarrenales/patología , Proteínas Supresoras de Tumor/metabolismo , Hormona Adrenocorticotrópica/metabolismo , Hormona Adrenocorticotrópica/farmacología , Anciano , Proteínas del Dominio Armadillo , Células Cultivadas , Femenino , Regulación de la Expresión Génica/efectos de los fármacos , Silenciador del Gen , Humanos , Hiperplasia , Gotas Lipídicas/efectos de los fármacos , Gotas Lipídicas/metabolismo , Masculino , Persona de Mediana Edad , Mutación/genética , Proopiomelanocortina/metabolismo , Progesterona Reductasa/genética , Progesterona Reductasa/metabolismo , Receptor de Melanocortina Tipo 2/metabolismo , Receptores Acoplados a Proteínas G/metabolismo , Análisis de Secuencia de ADN , Coloración y Etiquetado , Esteroide 17-alfa-Hidroxilasa/genética , Esteroide 17-alfa-Hidroxilasa/metabolismo , Proteínas Supresoras de Tumor/genética , Vasopresinas/farmacología
8.
Rev. bras. eng. biomed ; 28(4): 346-354, dez. 2012. ilus, graf, tab
Artículo en Portugués | LILACS | ID: lil-660857

RESUMEN

Uma identificação correta de transientes em sinais de ECG (Eletrocardiograma) pode auxiliar métodos de processamento de sinal de ECG, pois esse tipo de evento degrada o sinal e pode induzir a erros. Diante disso, o presente trabalho propõe uma arquitetura para a detecção desses fenômenos, seguindo a tendência atual da computação distribuída, na qual um sensor realiza a detecção dos transientes no momento da aquisição do sinal, e, em seguida, encaminha essa informação através de uma rede de comunicação de dados, desenvolvida especialmente para a automação hospitalar, até um dispositivo computacional que irá processar os dados ou então apresentá-los a um profissional capacitado para fazer a análise de forma manual. Para realizar a detecção de transientes, foi proposto um método matemático baseado na transformada Hilbert do sinal de ECG, aliado ao PM-AH (Protocolo Multiciclos para Automação Hospitalar), com adição de quadros neste, para que seja possível o envio da informação sobre a ocorrência de transientes junto aos dados do sinal de eletrocardiograma. Dentre os transientes possíveis, foi escolhido o ruído, por ser o fenômeno que mais interfere no processamento de sinais de ECG, onde testes foram realizados com a base de dados MIT-BIH Arrhythmia Database, enquanto uma análise matemática foi feita nos novos quadros do protocolo PM-AH, com o intuito de demonstrar a consistência do protocolo com esta adição.


A correct identification of transients in the ECG (electrocardiogram) can assist processing methods for ECG signals, since this type of event degrades the signal and can be misleading. Therefore, this paper proposes an architecture for detection of these phenomena, following the current trend of distributed computing, in which a sensor will detect transients at the time of signal acquisition, and then forward this information through a data communication network, designed specifically for hospital automation, to a computing device that will process the data or present it to a trained professional for manual analysis. To perform the detection of transients, a mathematical method based on the Hilbert transform of the ECG signal is proposed here, allied with the MP-HA (Multicycle Protocol for Hospital Automation), with the addition of frames, so that information on the occurrence of transients can be transmitted along with signal data of the electrocardiogram. Among the possible transients, noise was chosen because it is the phenomenon that interferes the most with the processing of ECG signals. Tests were performed using the MIT-BIH Arrhythmia Database, while a mathematical analysis was used in the new frames of the MP-HA protocol in order to demonstrate the consistency of the protocol with this addition.

SELECCIÓN DE REFERENCIAS
Detalles de la búsqueda